Myriad Genetics (NASDAQ:MYGN) Upgraded at Zacks Research

Zacks Research upgraded shares of Myriad Genetics (NASDAQ:MYGN) from a strong sell rating to a hold rating in a report issued on Thursday,Zacks.com reports.

Several other brokerages also recently commented on MYGN. Piper Sandler dropped their target price on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Wells Fargo & Company reduced their price objective on Myriad Genetics from $6.50 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 24th. TD Cowen reiterated a “hold” rating on shares of Myriad Genetics in a research note on Tuesday, November 4th. Finally, UBS Group reduced their price target on shares of Myriad Genetics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.17.

Myriad Genetics Trading Down 5.1%

Shares of MYGN stock opened at $4.61 on Thursday. Myriad Genetics has a 1-year low of $3.76 and a 1-year high of $11.44. The company has a market cap of $431.08 million, a price-to-earnings ratio of -1.17 and a beta of 1.90. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.12. The stock has a 50 day simple moving average of $5.61 and a 200-day simple moving average of $6.60.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.06. Myriad Genetics had a negative net margin of 44.38% and a negative return on equity of 6.35%. The firm had revenue of $209.80 million during the quarter, compared to analysts’ expectations of $207.57 million. During the same period last year, the business earned $0.03 earnings per share. Myriad Genetics’s revenue was down .4% compared to the same quarter last year. On average, equities research analysts expect that Myriad Genetics will post -0.3 EPS for the current fiscal year.

Insider Transactions at Myriad Genetics

In related news, Director S. Louise Phanstiel acquired 48,000 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $4.66 per share, with a total value of $223,680.00. Following the purchase, the director directly owned 281,951 shares in the company, valued at approximately $1,313,891.66. This trade represents a 20.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders purchased a total of 104,507 shares of company stock worth $494,548 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Myriad Genetics

Several large investors have recently modified their holdings of MYGN. EverSource Wealth Advisors LLC increased its stake in shares of Myriad Genetics by 2,333.3% during the second quarter. EverSource Wealth Advisors LLC now owns 4,672 shares of the company’s stock valued at $25,000 after purchasing an additional 4,480 shares in the last quarter. Quarry LP increased its stake in Myriad Genetics by 155.6% during the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock valued at $27,000 after purchasing an additional 2,657 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in Myriad Genetics by 1,088.7% in the third quarter. Hantz Financial Services Inc. now owns 4,089 shares of the company’s stock worth $30,000 after buying an additional 3,745 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Myriad Genetics by 407.3% in the second quarter. Nisa Investment Advisors LLC now owns 5,773 shares of the company’s stock worth $31,000 after buying an additional 4,635 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Myriad Genetics by 129.6% during the fourth quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after buying an additional 2,818 shares during the last quarter. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Myriad Genetics News Summary

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Director S. Louise Phanstiel completed multiple open‑market purchases totaling roughly 104,507 shares across Feb. 25–27 (average prices ~ $4.66–$4.80), increasing her stake substantially — a strong signal of insider confidence that can attract buyers. SEC Form 4 filing
• Positive Sentiment: Zacks Research upgraded MYGN from “strong sell” to “hold,” which can reduce model-driven selling and support demand from investors using Zacks screens. Zacks.com
• Neutral Sentiment: Media coverage (TipRanks, MarketBeat, InsiderTrades) amplified the insider activity — this typically increases short‑term volume and retail attention but does not change fundamentals by itself. TipRanks article
• Negative Sentiment: Company updated Q1 FY2026 revenue guidance to $200.0M–$203.0M vs. consensus ~$203.5M and did not provide EPS guidance — the slightly lower top‑line outlook and missing EPS figure create short‑term uncertainty that can pressure the shares. (Company guidance release)
• Negative Sentiment: Recent analyst moves include price‑target cuts (e.g., UBS and Wells Fargo lowering targets to ~$6.00) and mixed ratings — these downward revisions contribute to bearish near‑term sentiment despite some longer‑term analyst support. MarketBeat analyst summary

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.